Editorial
Copyright ©2010 Baishideng.
World J Gastroenterol. May 7, 2010; 16(17): 2067-2074
Published online May 7, 2010. doi: 10.3748/wjg.v16.i17.2067
Table 1 Overview of RCT trials 2004-2008 of alvimopan
AuthorNumber of patientsPrimary end pointGI2 improvement (h)GI3 improvement (h)Hazard ratioDCO improvement (h)
Wolff et al[57]510GI320.0115.011.28113.01
28.0222.021.54220.02
Viscusi et al[56]666GI316.417.511.20114.21
13.729.921.24215.22
Delaney et al[55]451GI315.2114.111.45114.01
10.527.521.2827.22
Ludwig et al[53]654GI220.0216.021.50217.02
Buchler et al[58]911GI314.318.511.1818.11
10.724.821.3725.92
Table 2 Effect of interventions to improve gastrointestinal recovery and reduce LOS
TrialsType of studyInterventionImprovement passage flatusImprovement first bowel movementDecrease in LOS
Noble et al[52]Meta analysisChewing gum14 h23 h1.1 d
Delaney et al[54]Pooled analysisAlvimopan12 h1 (6 mg)15 h2 (6 mg)18.4 h3
15 h1 (12 mg)18 h2 (12 mg)
Delaney et al[28]Observational multicenter studyLaparoscopic surgeryNA0.7 d21.7 d3
Walter et al[69]Meta analysisERPNANA3.64 d